$ 50,611$ 45,283$ 181,906$ 156,313Add interest expense on senior convertible notes, net of income tax
6256252,5012,501Non-GAAP adjusted diluted net income
$ 51,236$ 45,908$ 184,407$ 158,814Shares used in computing GAAP diluted net income per share
84,49390,93488,07690,081Shares used in computing Non-GAAP adjusted diluted net income per share
84,49390,93488,07690,081GAAP diluted net income per share
.47Non-GAAP adjusted diluted net income per share
.76Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income:
1. Non-cash interest expense: Non-GAAP adjusted net income excludes certain non-cash interest expense resulting from the change in the method of accounting for our convertible notes which became effective in 2009. We believe that excluding the non-cash portion of our interest expense allows management and investors an alternative view of our financial results "as if" our net income reflected only the cash portion of our interest expense.
2. Purchase accounting and product acquisition related adjustments: Non-GAAP adjusted net income excludes certain items related to our acquisitions. The excluded items include charges related to amortization of intangible assets arising from acquisitions, changes in the fair value of future contingent consideration and upfront fees or milestone payments under license agreements.
3. Stock option expense: Non-GAAP adjusted net income excludes the impact of our stock compen
|SOURCE ViroPharma Incorporated|
Copyright©2010 PR Newswire.
All rights reserved